OUR SCIENCE
A new generation of therapies
miragene pipeline
BTK
(3rd-gen BTKi with once-daily potential)
Chronic spontaneous urticaria
Other indications to be disclosed
BDCA2
(pDC depleting mAb)
Cutaneous lupus erythematousus
Systemic lupus erythematousus
Two targets to be disclosed
(bi-specific mAb with extended half-life)
To be disclosed
led by Partners
ILT7
(mAb)
To be disclosed
IL7Ra
(mAb)
To be disclosed
*Formed partnership with Aditum Bio to create Celexor Bio
+Global rights out-licensed to a company incubated by MPM
MAG-007
A PHASE 2–READY, NON-COVALENT, REVERSIBLE, BRAIN-PENETRANT BTK INHIBITOR WITH BEST-IN-CLASS POTENTIAL
MAG-007 is a Phase 2–ready, non-covalent, reversible, brain-penetrant BTK inhibitor (BTKi) with best-in-class potential. It is designed to combine high potency, a wide therapeutic window, a favorable safety profile, and the convenience of once-daily dosing. Supported by long-term animal toxicology studies and Phase 1 clinical data, MAG-007 has the potential to mitigate key risks observed with some BTK inhibitors, including liver enzyme elevations and bleeding, at anticipated therapeutic dose levels. With an approximately 31-hour half-life, MAG-007 provides a differentiated PK/PD profile that supports sustained target coverage with once-daily dosing.
MAG-017
A pDC depleting anti-BDCA2 mAb
MAG-017, a plasmacytoid dendritic cell (pDC)–depleting anti-BDCA2 monoclonal antibody, has the potential to provide clinical benefit across multiple inflammatory and autoimmune diseases, including lupus. Currently in preclinical development, MAG-017 combines two complementary mechanisms relevant to lupus pathogenesis: BDCA2-mediated inhibition of type I interferon (IFN-I) signaling and direct depletion of pDCs, the major cellular source of IFN-I. In preclinical studies, MAG-017 has demonstrated greater potency in suppressing IFN-I production and in eliminating pDCs compared with leading competitive molecules.
QuadraTek®:
a platform for innovation
Our proprietary QuadraTek® platform is designed to create highly differentiated biologic drug candidates with the potential to better address unmet needs in immunologic and inflammatory diseases.
Four parallel systems to generate diversified, high-performing leads
Proprietary functional assays to select competitive, differentiated drug candidates
Advanced protein engineering to optimize different aspects of a product
